APA (7th ed.) Citation

Dowlati, A., Harvey, R. D., Carvajal, R. D., Hamid, O., Klempner, S. J., Kauh, J. S. W., . . . Wesolowski, R. (2021). LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: Phase 1 dose-escalation trial. Investigational new drugs, 39(4), 1057-1071. https://doi.org/10.1007/s10637-021-01084-8

Chicago Style (17th ed.) Citation

Dowlati, Afshin, et al. "LY3022855, an Anti–colony Stimulating Factor-1 Receptor (CSF-1R) Monoclonal Antibody, in Patients with Advanced Solid Tumors Refractory to Standard Therapy: Phase 1 Dose-escalation Trial." Investigational New Drugs 39, no. 4 (2021): 1057-1071. https://doi.org/10.1007/s10637-021-01084-8.

MLA (9th ed.) Citation

Dowlati, Afshin, et al. "LY3022855, an Anti–colony Stimulating Factor-1 Receptor (CSF-1R) Monoclonal Antibody, in Patients with Advanced Solid Tumors Refractory to Standard Therapy: Phase 1 Dose-escalation Trial." Investigational New Drugs, vol. 39, no. 4, 2021, pp. 1057-1071, https://doi.org/10.1007/s10637-021-01084-8.